← Back to All US Stocks

AVAH Stock Analysis - Aveanna Healthcare Holdings, Inc. AI Rating

AVAH Nasdaq Services-Home Health Care Services DE CIK: 0001832332
Recently Updated • Analysis: Mar 20, 2026 • SEC Data: 2026-01-03
AI Rating
HOLD
62% Confidence

📊 AVAH Key Takeaways

Revenue: $2.4B
Net Margin: 9.2%
Free Cash Flow: $117.1M
Current Ratio: 1.32x
Debt/Equity: 6.68x
EPS: $1.05
AI Rating: HOLD with 62% confidence

Investment Thesis

Aveanna demonstrates solid operational performance with strong 20.2% revenue growth and healthy profitability metrics, but faces concerning leverage with a 6.68x debt-to-equity ratio and weak interest coverage of 1.8x. The exceptional 115.7% ROE is artificially inflated by minimal equity base rather than operational excellence, masking underlying financial stress from high debt levels.

AVAH Strengths

  • + Strong revenue growth of 20.2% YoY indicating market expansion in home healthcare
  • + Solid profitability with 33.3% gross margin and 10.2% operating margin showing pricing power
  • + Positive free cash flow of $117.1M (4.8% FCF margin) with capex discipline
  • + Adequate liquidity with 1.32x current ratio supporting operational needs

AVAH Risks

  • ! Dangerously high leverage at 6.68x debt-to-equity ratio with $1.3B long-term debt against $194.5M equity
  • ! Weak interest coverage of 1.8x leaves minimal cushion for debt service in economic downturns
  • ! Minimal equity base creates refinancing risk and limits financial flexibility for acquisitions or downturns
  • ! Net income flat YoY (+0.0%) despite 20.2% revenue growth suggests margin compression or one-time items
  • ! High insider trading activity (22 Form 4 filings in 90 days) warrants monitoring for potential concerns

Key Metrics to Watch

AVAH Financial Metrics

Revenue
$2.4B
Net Income
$225.0M
EPS (Diluted)
$1.05
Free Cash Flow
$117.1M
Total Assets
$2.0B
Cash Position
$193.3M

💡 AI Analyst Insight

The relatively thin 4.8% FCF margin may limit capital allocation flexibility.

AVAH Profitability Ratios

Gross Margin 33.3%
Operating Margin 10.5%
Net Margin 9.2%
ROE 115.7%
ROA 11.2%
FCF Margin 4.8%

AVAH vs Default Sector

How Aveanna Healthcare Holdings, Inc. compares to Default sector averages

Net Margin
AVAH 9.2%
vs
Sector Avg 12.0%
AVAH Sector
ROE
AVAH 115.7%
vs
Sector Avg 15.0%
AVAH Sector
Current Ratio
AVAH 1.3x
vs
Sector Avg 1.8x
AVAH Sector
Debt/Equity
AVAH 6.7x
vs
Sector Avg 0.7x
AVAH Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

AVAH Balance Sheet & Liquidity

Current Ratio
1.32x
Quick Ratio
1.32x
Debt/Equity
6.68x
Debt/Assets
90.3%
Interest Coverage
1.83x
Long-term Debt
$1.3B

AVAH 5-Year Financial Trend

AVAH 5-year financial data: Year 2022: Revenue $1.8B, Net Income -$76.5M, EPS $-0.69. Year 2023: Revenue $1.9B, Net Income -$662.0M, EPS $-3.57. Year 2024: Revenue $2.0B, Net Income -$134.5M, EPS $-0.71. Year 2026: Revenue $2.4B, Net Income -$10.9M, EPS $-0.06.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Aveanna Healthcare Holdings, Inc.'s revenue has grown significantly by 36% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.06 indicates the company is currently unprofitable.

AVAH Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
4.8%
Free cash flow / Revenue

AVAH Quarterly Performance

Quarterly financial performance data for Aveanna Healthcare Holdings, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $509.0M $14.1M $0.06
Q2 2025 $505.0M $2.7M $0.01
Q1 2025 $490.7M $5.2M $0.03
Q3 2024 $478.0M -$40.1M $-0.21
Q2 2024 $471.9M $2.7M $0.01
Q1 2024 $466.4M -$11.2M $-0.06
Q3 2023 $443.0M $24.3M $0.13
Q2 2023 $443.0M -$6.4M $-0.03

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

AVAH Capital Allocation

Operating Cash Flow
$125.9M
Cash generated from operations
Capital Expenditures
$8.8M
Investment in assets
Dividends
None
No dividend program

AVAH SEC Filings

Access official SEC EDGAR filings for Aveanna Healthcare Holdings, Inc. (CIK: 0001832332)

📋 Recent SEC Filings

Date Form Document Action
Mar 19, 2026 10-K avah-20260103.htm View →
Mar 19, 2026 8-K avah-20260319.htm View →
Mar 12, 2026 8-K avah-20260309.htm View →
Feb 27, 2026 8-K avah-20260227.htm View →
Feb 20, 2026 8-K avah-20260217.htm View →

Frequently Asked Questions about AVAH

What is the AI rating for AVAH?

Aveanna Healthcare Holdings, Inc. (AVAH) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.

What are AVAH's key strengths?

Strong revenue growth of 20.2% YoY indicating market expansion in home healthcare. Solid profitability with 33.3% gross margin and 10.2% operating margin showing pricing power.

What are the risks of investing in AVAH?

Dangerously high leverage at 6.68x debt-to-equity ratio with $1.3B long-term debt against $194.5M equity. Weak interest coverage of 1.8x leaves minimal cushion for debt service in economic downturns.

What is AVAH's revenue and growth?

Aveanna Healthcare Holdings, Inc. reported revenue of $2.4B.

Does AVAH pay dividends?

Aveanna Healthcare Holdings, Inc. does not currently pay dividends.

Where can I find AVAH SEC filings?

Official SEC filings for Aveanna Healthcare Holdings, Inc. (CIK: 0001832332) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is AVAH's EPS?

Aveanna Healthcare Holdings, Inc. has a diluted EPS of $1.05.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 20, 2026 | Data as of: 2026-01-03 | Powered by Claude AI